News & Events
Probiodrug to Attend and Present at European Conferences in May 2016
Published: 03 May 2016

Probiodrug to Attend and Present at European Conferences in May 2016

HALLE/SAALE, Germany, 3 May 2016 - Probiodrug AG ("Probiodrug", Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease, announces that the company is scheduled to attend the following conferences:

(1) Bio€quity Europe 2016
10 - 11 May 2016, Scandic Hotel, Copenhagen, Denmark

Dr Hendrik Liebers, CFO, to present on Tuesday, 10 May at 11:40 am CET in Ball Room 1

Now in its 17th year, Bio€quity Europe is a major industry event for financial dealmakers looking for investor-validated life science companies and for pharmaceutical licensing professionals to assess top prospects. Bio€quity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals. Delegates from over 20 nations attended the event last year.

(2) analytica 2016
10 - 13 May 2016, Messe Munich, Germany

Dr Hendrik Liebers, CFO, to join the panel on Thursday, 12 May, at 03:30 pm CET entitled: "Biotech and the stock exchange: A marriage of convenience or elite partners?"

The analytica conference aims to promote interactions between scientists and industry representatives to enable interdisciplinary collaboration on an international level. The Finance Day on Thursday, 12 May, will enable biotech entrepreneurs to meet with investors. Speakers will discuss the latest financing trends as well as collaborations between big pharma and biotech companies. This year's program will focus on which financing alternatives are best for companies and tips on how to enter the US market.


For more information, please contact:

Dr Konrad Glund, CEO

Hume Brophy
Supriya Mathur, Eva Haas, Alexia Faure
Tel: +44 (0) 20 7862 6381

Notes to Editors:
About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer's disease.

Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes - the DP4 inhibitors - which provided the basis for a novel class of antidiabetics - the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.

Today Probiodrug's aim is to become a leading company in the development of Alzheimer's disease treatments and to thereby provide a better life for Alzheimer's disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer's disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company's view, with a leading position in this field of research.

About Alzheimer's disease
Alzheimer's disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer's disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, over 46 million people worldwide currently live with the condition and this number is expected to increase to 132 million by 2050. Alzheimer's also has an estimated, global societal cost of US$ 818 billion (World Alzheimer Report 2015).

Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.